Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases.
A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s) of action involved in therapeutic activity or related to the insurgence of specific adverse events. Early chapters focus on general characteristics of TKIs, typology, and classification of adverse events, while the final chapters analyze TKIs as AE inducers and classes of AEs by system or organ involvement.
This comprehensive resource compiles and critically reviews all of the relevant safety data for this class of drugs, with the goal of improving the understanding of pathogenesis and facilitating the prevention, monitoring, and management of these adverse events.
- Offers a unique and comprehensive publication on the adverse events associated with a new and fast-growing class of medicines
- Provides a systematic analysis of adverse events aimed at better prevention through understanding and offering insights for the development of safer drugs
- Uses practical guidelines to establish a leading reference on this class of drugs for educators, researchers, drug developers, clinicians, safety professionals, and more
|Sold by:||Barnes & Noble|
|File size:||8 MB|
About the Author
School of Medicine and Surgery
Coordinator of the Teachers’ Committee for the Master in Translational Biomedicine
Universita degli Studi di Verona, Italy
Table of ContentsPart I: General Aspects 1. Introduction 2. Protein and Lipid Kinases 3. Kinase Inhibitors 4. Adverse Events
Part II: Oncotargeted Kinase Inhibitors 5. Imatinib 6. Gefitinib 7. Erlotinib 8. Sorafenib 9. Sunitinib 10. Dasatinib 11. Lapatinib 12. Nilotinib 13. Pazopanib 14. Vandetanib 15. Vemurafenib 16. Crizotinib 17. Ruxolitinib 18. Axitinib 19. Bosutinib 20. Regorafenib 21. Cabozantinib 22. Ponatinib 23. Dabrafenib 24. Trametinib 25. Adatinib 26. Idelalisib 27. Ibrutinib
Part III: Overview 28. Kinase Inhibitors as Adverse Event Inducers 29. Kinase Inhibitors as Drug Class Events 30. Conclusion and Perspectives